Researchers conducted a single-center, cross-sectional study to examine the relationship between patient-reported quality-of-life (QOL), adverse events (AEs), and treatment characteristics (including tumor type, drug class, number of cycles, and treatment intent). The study’s findings were presented at the 2017 ASCO Annual Meeting.

Patients with advanced-stage cancer experience frequent hospitalizations, followed by post-discharge transitions of care that can influence patient quality of life. A study presented at the ASCO Annual Meeting sought to examine predictors of discharge location for these patients.

Older adults with cancer can have limited functional and health status; however, occupational (OT) and physical therapy (PT) are underused resources of care in this patient population. Researchers evaluated an outpatient CAncer REhabilitation (CARE) intervention program for this older adults in comparison to usual care. The study’s findings were presented at the ASCO Annual Meeting.

Patients with platinum-sensitive relapsed (PSR) serous ovarian cancer (SOC) have poor survival outcomes, with the median progression-free survival (PFS) after chemotherapy less than six months in many patients. Based on results from the SOLO2 study that found that maintenance olaparib after response to chemotherapy resulted in a significant improvement in PFS compared to placebo (median PFS = 19.1 versus 5.5 months) in patients with germline BRCA mutation PSR SOC (hazard ratio [HR] = 0.30; 95% CI = 0.22–0.41; p < 0.0001), researchers assessed the impact of health-related quality-of-life (HRQOL). The researchers presented the study at the ASCO Annual Meeting.